Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004030 · ClinicalTrials.gov registry record · Phase 1
VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00004030: Completed Phase 1 study, sponsored by Georgetown University.
NCT00004030 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004030, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of VX-853 in treating patients who have solid tumors who are receiving liposomal doxorubicin.
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG VX-853
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1996-03 |
| Est. Completion | 2001-01 |
| Phase | Phase 1 |
What the finished NCT00004030 record still lists
NCT00004030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT00004030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004030 about?
NCT00004030 is a clinical study titled "VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of VX-853 in treating patients who have solid tumors who are receiving liposomal doxorubicin.
What is the current status of trial NCT00004030?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 1996-03. Estimated completion is 2001-01.
What interventions are being tested in trial NCT00004030?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG), VX-853 (DRUG).
Who is sponsoring clinical trial NCT00004030?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004030's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia